BRKR · Bruker Corporation
Price
Snapshot
50 fields · last close| Market Cap | $9.72B |
| P/E | — |
| Float | 111.2M |
| Beta | 1.26 |
| Volatility 30D | 62.2% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | High |
| Clavix score | 61.9 |
| Price | 58.56 |
| Change | −8.20% |
| Prev Close | 63.79 |
| Open | 65.39 |
| Day Low | 59.12 |
| Day High | 68.98 |
| Avg Vol | 2 |
| Avg $ Vol | $156.4M |
| 52W High | 66.98 |
| 52W Low | 32.37 |
| 52W Pos | 75.7% |
| From High | −12.57% |
| From Low | +80.91% |
| Max DD 1Y | −39.85% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.19% |
| SMA 50 | −0.66% |
| SMA 200 | +16.28% |
| RSI (14) | 59.9 |
| Vol 90D | 68.6% |
| Vol 1Y | 58.6% |
| 1Y Range | 32–67 |
| Daily bars | 549 |
| Perf Week | +2.89% |
| Perf Month | +5.44% |
| Perf Quarter | +24.42% |
| Perf Half Y | +50.80% |
| Perf Year | +64.79% |
| Perf YTD | +21.72% |
| Prev Day | −8.20% |
| Clavix | C+ |
| Debt / Eq | 0.76 |
| Curr Ratio | 1.73 |
| Int Cover | 1.8× |
| FCF Margin | 1.3% |
| Rev Growth | +2.1% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 17 / 19 |
Clavix risk grade
regraded every trading dayBRKR grades C+, 61.9 of 100. Steadiest on Sector Resilience (65), most exposed on Price Stability (39, fragile). 0 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 17 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| BRKR | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.26 | 1.16 |
| 30-day realized volatilityannualized, from daily closes | 62.2% | 30.3% |
| Max drawdown, past yearworst peak-to-trough fall | −39.8% | — |
| Typical daily movemedian absolute daily change | 1.92% | — |
| Days beyond ±3%of the last 252 sessions | 81 (32%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BRKR | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.26 | 1.16 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BRKR | |
|---|---|
| 1 week | +2.9% |
| 1 month | +5.4% |
| Year to date | +21.7% |
| 1 year | +64.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BRKR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 4 Aug |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 2 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| BRKR | |
|---|---|
| Revenue growthyear over year | +2.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openBruker reported quarterly earnings of $0.56 per share, beating the $0.42 consensus estimate and exceeding $0.45 earned a year earlier. The headline also says revenue surpassed estimates, but no revenue amount or growth rate is provided.
Bruker’s board declared a quarterly cash dividend of $3.9844 per share on its 6.375% Series A mandatory convertible preferred stock. Payment is scheduled for December 1, 2026, to shareholders of record on November 15, 2026.
Bruker and Charité released a draft human blood-protein map covering more than 179,000 distinct protein variants, built on Bruker's timsTOF mass spectrometry (a tool that identifies proteins by their weight and structure). They published the data as a free online preprint to support research.
Bruker launched new lab-analysis workflows (timsUltra AIP and timsOmni) for mass spectrometry equipment, extending into protein sequencing, glycopeptide analysis, structural proteomics, and oligonucleotide characterization. Despite a strong year-to-date share price return of 24.13%, the stock fell 7.77% over the prior 7 days.
Bruker announced that researchers at the university hospital Charité in Berlin published a scientific preprint using Bruker's timsTOF mass spectrometry equipment to map the proteins found in human blood at the level of individual protein variants (called proteoforms). The preprint was posted on bioRxiv on September 28, 2026.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | QIAGEN N.V. | B+ | $10.50B | 25.58 | 0.57 | Compare |
| AVTR | Avantor, Inc. | B- | $10.60B | — | 0.95 | Compare |
| TXG | 10x Genomics, Inc. | D+ | $8.51B | — | 2.07 | Compare |
| RGEN | Repligen Corporation | B- | $11.39B | 232.35 | 1.17 | Compare |
| TECH | Bio-Techne Corporation | A | $11.42B | 62.75 | 1.26 | Compare |
| TEM | Tempus AI, Inc. | D- | $13.79B | — | 2.50 | Compare |
| CRL | Charles River Laboratories International, Inc. | B- | $15.58B | — | 1.34 | Compare |
| RVTY | Revvity, Inc. | B | $17.79B | 75.29 | 1.06 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.